Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide

Lildholdt, Torben; Rundcrantz, Hans; Lindqvist, Niclas

doi:10.1111/j.1365-2273.1995.tb00007.x

Cited by 182 publications

(158 citation statements)

References 11 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Treatment of NP consists of medical and/or surgical treatment. Topical glucocorticosteroid therapy has a well established role in the management of NP, since it has proven efficacy on symptoms and size of polyps and may help prevent the recurrence of NP after surgery (40). Surgical management Difficult asthma of NP aims to restore normal nasal function, including nasal ventilation and sinus drainage, when topical GCS alone are insufficient.…”

Section: Upper Airway Diseasesmentioning

confidence: 99%

Difficult asthma

Garcia

and

Humbert

2003

Allergy

View full text Add to dashboard Cite

Section: Upper Airway Diseasesmentioning

confidence: 99%

Difficult asthma

Garcia

and

Humbert

2003

Allergy

View full text Add to dashboard Cite

“…93 To date, however, there have been only a few published studies focusing on INS treatment outcomes in nasal polyposis. Small short-term studies from the 1990s examined the use of aqueous and powder forms of budesonide [97][98][99] and found it to be efficacious in the treatment of small-to largesized polyps. Other studies in patients with severe or bilateral polyposis found evidence of similar efficacy and tolerability of fluticasone propionate or beclomethasone dipropionate, with some evidence that fluticasone had a more rapid onset of action.…”

Section: Acute Rhinosinusitis and Nasal Polyposis: Association With Amentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

“…The topic corticosteroid therapy is a well-established part in the treatment of allergic rhinitis [15] and chronic sinusitis [16,17]. Mometasone nasal spray showed the greatest effectiveness in reducing fibroblast cultures in nasal polyps followed by beclomethasone [18].…”

Section: Discussionmentioning

confidence: 99%

Effect of Laser Treatment on Olfactory Dysfunction

Göktas

Lau

Fleiner

2011

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Olfactory disorders are not rare and affect quality of life in patients. The purpose of our study was to evaluate the outcomes of an outpatient-based diode laser inferior turbinate reduction (ITR) in otherwise therapyrefractory olfactory disorder. In a prospective clinical investigation, 20 patients (7 male, 13 female, mean age 53.2 ± 15.34) with olfactory disorder and 10 patients (8 male, 2 female, mean age 52.5 ± 17.55) without olfactory disorder underwent ITR under videoendoscopic control with a continuous diode laser in ''contact'' mode after topical anesthetic preparation. Treatment efficiency was assessed before and 2 months after surgery. Subjective nasal airflow (NA) and the olfactory function were rated by means of visual analogue scales (VAS). Olfactory function was assessed using the ''Sniffin' Sticks'' test battery. VAS showed very low median values for intraoperative pain (0) [0-1.20] and high postoperative patient satisfaction (8) [5][6][7][8][9]. After 2 months there was no significant improvement of objective olfactory function as measured by the TDI score (threshold, discrimination and identification). The VAS displayed a slight significant improvement in the group of patients with olfactory disorder from 2.95 to 3.65 (P = 0.04). After 2 months, NA data revealed a statistically significant improvement of subjective VAS from 5.05 to 6.25 (P \ 0.0005) and of objective NA from 353.77 to 443.50 (P = 0.007) as measured by rhinomanometry in both groups. Outpatient diode laser ITR represents an effective option providing recovery by NA improvement but not a significant improvement of the olfactory function.

show abstract

Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide

Cited by 182 publications

References 11 publications

Difficult asthma

Difficult asthma

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Effect of Laser Treatment on Olfactory Dysfunction

Contact Info

Product

Resources

About